PlatoScience

PlatoScience operates at the intersection of neuroscience, medical devices, digital health, and consumer electronics. Its core modality is transcranial direct current stimulation, or tDCS, delivered through dedicated headsets and supported by mobile and clinician software. The company’s differentiation is less about a standalone stimulation device than an integrated workflow: PlatoCare and PlatoWork hardware connect with PlatoApp and a clinician dashboard that enables remote setup, monitoring, and repeated sessions. The company also emphasizes clinical and research use through certification and collaboration programs. Its website describes ISO 13485, EN60601, and EU MDR-related capabilities, including PlatoCare’s classification as an EU MDR Class IIa device for depression. PlatoScience’s market position is therefore best characterized as a small, specialized neurotechnology provider with both professional healthcare and research-facing channels, rather than a scaled mass-market electronics company.

PlatoScience was founded in Copenhagen on Aug 26, 2015 and has remained a small company, with an employee range of one to ten and six documented current positions. Its financing history shows an early angel round dated Dec 20, 2018, an $81,868 grant dated Jan 1, 2019, and two seed rounds dated Jun 29, 2020 and Feb 9, 2022. The grant is the only round with a disclosed amount, so the scale of private-capital growth cannot be measured reliably. The clearest product inflection is the expansion from a tDCS headset into an integrated care and research platform. PlatoScience now describes PlatoCare and PlatoWork hardware alongside PlatoApp, a clinician dashboard, professional certification, and a research collaboration program. The company reports use in more than 80 countries, by over 200 clinics, and across more than 100,000 hours of stimulation, but these are company-reported operating indicators rather than independently verifiable growth metrics. The trajectory suggests gradual product and regulatory maturation, with limited visibility into recent commercial acceleration.